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Leukocytic Toll-Like Receptor-2 and Reduced by Systemic
Administration of a Novel Anti–Toll-Like
Receptor-2 Antibody
Fatih Arslan, MD; Mirjam B. Smeets, PhD; Luke A.J. O’Neill, PhD; Brian Keogh, PhD;
Peter McGuirk, PhD; Leo Timmers, MD, PhD; Claudia Tersteeg, MSc; Imo E. Hoefer, MD, PhD;
Pieter A. Doevendans, MD, PhD; Gerard Pasterkamp, MD, MSc, PhD; Dominique P.V. de Kleijn, PhD
Background—Reperfusion therapy for myocardial infarction is hampered by detrimental inflammatory responses partly
via Toll-like receptor (TLR) activation. Targeting TLR signaling may optimize reperfusion therapy and enhance cell
survival and heart function after myocardial infarction. Here, we evaluated the role of TLR2 as a therapeutic target using
a novel monoclonal anti-TLR2 antibody.
Method and Results—Mice underwent 30 minutes of ischemia followed by reperfusion. Compounds were administered 5
minutes before reperfusion. Cardiac function and dimensions were assessed at baseline and 28 days after infarction with
9.4-T mouse magnetic resonance imaging. Saline and IgG isotype treatment resulted in 34.53.3% and 31.42.7%
infarction, respectively. Bone marrow transplantation experiments between wild-type and TLR2-null mice revealed that
final infarct size is determined by circulating TLR2 expression. A single intravenous bolus injection of anti-TLR2
antibody reduced infarct size to 18.92.2% (P0.001). Compared with saline-treated mice, anti-TLR2–treated mice
exhibited less expansive remodeling (end-diastolic volume 68.22.5 versus 76.83.5 L; P0.046) and preserved
systolic performance (ejection fraction 51.02.1% versus 39.92.2%, P0.009; systolic wall thickening 3.36.0%
versus 22.04.4%, P0.038). Anti-TLR2 treatment significantly reduced neutrophil, macrophage, and T-lymphocyte
infiltration. Furthermore, tumor necrosis factor-, interleukin-1, granulocyte macrophage colony-stimulating factor,
and interleukin-10 were significantly reduced, as were phosphorylated c-jun N-terminal kinase, phosphorylated p38
mitogen-activated protein kinase, and caspase 3/7 activity levels.
Conclusions—Circulating TLR2 expression mediates myocardial ischemia/reperfusion injury. Antagonizing TLR2 just 5
minutes before reperfusion reduces infarct size and preserves cardiac function and geometry. Anti-TLR2 therapy exerts
its action by reducing leukocyte influx, cytokine production, and proapoptotic signaling. Hence, monoclonal anti-TLR2
antibody is a potential candidate as an adjunctive for reperfusion therapy in patients with myocardial infarction. (Circulation.
2010;121:80-90.)
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E
arly restoration of blood flow through the occluded
coronary artery is currently the most effective therapy
to limit infarct size and to preserve cardiac function and
geometry after acute myocardial infarction (MI).1 Never-
theless, reperfusion alone is insufficient to save endan-
gered myocardium because complications resulting from
loss of viable myocardium are still common after MI even
after restoration of blood flow. Furthermore, studies have
clearly demonstrated that reperfusion after ischemia causes
additional cell death and increases infarct size (IS), called
myocardial ischemia/reperfusion (I/R) injury. Many inter-
ventions aiming at reducing myocardial I/R injury have
been proven to be successful in experimental studies but
have failed in clinical settings.2 Administration of experi-
mental compounds before the ischemic period, rather than
in the late ischemic period before reperfusion, is one
reason for the failure of successful translation in the
clinic.3,4
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Myocardial I/R injury is characterized by a rapid increase
in cytokines and chemokines and influx of leukocytes into the
endangered myocardial region.3 Inflammatory responses after
myocardial I/R injury are detrimental for cell survival and
extracellular matrix integrity via enhanced activation of
proapoptotic signaling pathways. The extent of cardiomyo-
cyte apoptosis determines IS and subsequent heart function.
Mitogen-activated protein kinases c-Jun N-terminal kinase
(c-JNK) and p38 mitogen-activated protein kinase (p38-
MAPK) are well documented as proapoptotic mediators of
myocardial I/R injury.5 Indeed, cardiac infarct healing and
post-MI remodeling are also processes in which leukocytes,
cytokines, and chemokines play both a beneficial and a
detrimental role.6 For example, administration of methylpred-
nisolone results in more frequent cardiac ruptures7 despite IS
reduction in animal models.8,9 Hence, the challenge lies in
ameliorating the detrimental inflammatory response while not
affecting the tissue repair response.
Modulating Toll-like receptor (TLR) activation may en-
hance the “good” and blunt the “bad” of the inflammatory
response after myocardial I/R injury. TLRs are expressed by
leukocytes and recognize pathogen-associated molecular pat-
terns to defend the host from invading microorganisms. TLRs
are also capable of recognizing endogenous “danger signals”
released during cell death.10 More intriguing is the fact that
TLRs are also expressed on cells with no direct role in host
innate immune responses, like endothelial cells11 and cardio-
myocytes.12 On activation, TLRs exert their inflammatory
response through nuclear factor-B (NF-B) translocation to
the nucleus.13 Therefore, inhibition of TLRs may provide new
therapeutic options after MI. This view is supported by recent
observations in TLR-knockout mice. For example, ex vivo
experiments show that TLR2-knockout (TLR2
/) hearts
perform better than wild-type (WT) hearts after myocardial
I/R injury.14 TLR2
/ mice are protected against endothelial
dysfunction after myocardial I/R injury,15 whereas TLR2
stimulation impairs cardiomyocyte contractility via NF-B.16
Furthermore, deficient TLR2 or TLR4 signaling in mice
prevents adverse cardiac remodeling, resulting in preserved
cardiac function and geometry after MI.17,18 This evidence
suggests that preventing TLR activation may be beneficial
after MI through the prevention of myocardial I/R injury and
enhancement of tissue repair responses. In the present study,
we show in vivo the relative contribution of TLR2 in
parenchymal and circulating blood cells to myocardial I/R
injury. In addition, we demonstrate that treatment with a
novel anti-TLR2 monoclonal antibody reduces myocardial
I/R injury and preserves cardiac function and geometry.
Methods
Animals and Experimental Design
TLR2
/ animals were backcrossed for 6 generations into a C57Bl6
background. Male C57Bl6/J and C57Bl6-TLR2
/ mice (age, 10 to
12 weeks; weight, 25 to 30 g) received standard diet and water ad
libitum. Experimental compounds were administered via the tail vein
5 minutes before reperfusion. Mice were given 250 L stock with
either phosphate-buffered saline or IgG isotype 10 mg/kg as a
negative control (R&D Systems, Minneapolis, Minn), SB239063 at
0.5 mg/kg (a p38-MAPK inhibitor) as a positive control (Alexis
Corp, Lausen, Switzerland), and OPN-301 at 10 mg/kg (kindly
provided by Opsona Therapeutics Ltd). When possible, recommen-
dations from the National Heart, Lung, and Blood Institute Working
Group on the Translation of Therapies for Protecting the Heart From
Ischemia4 were applied; the surgeon was blinded to treatment.
Digital photos of infarcts were encrypted before being analyzed by
the researcher. Heart function and geometry assessment was done by
a technician blinded to treatment. All animal experiments were
performed in accordance with the national guidelines on animal care
and with prior approval by the Animal Experimentation Committee
of Utrecht University.
Myocardial I/R Injury In Vivo
Mice were anesthetized with a mixture of Fentanyl (Jansen-Cilag)
0.05 mg/kg, Dormicum (Roche) 5 mg/kg, and medetomidine 0.5
mg/kg through an intraperitoneal injection. Atropine 0.05 mg/kg SC
was administered after coronary ligation. A core body temperature of
37°C was maintained during surgery by continuous monitoring
with a rectal thermometer and automatic heating blanket. Mice were
intubated and ventilated (Harvard Apparatus Inc, Holliston, Mass)
with 100% oxygen. The left coronary artery was ligated for 30
minutes with an 8-0 Ethilon (Ethicon) suture with a section of
polyethylene-10 tubing placed over the left coronary artery. Ischemia
was confirmed by bleaching of the myocardium and ventricular
tachyarrhythmia. Reperfusion was initiated by releasing the ligature
and removing the polyethylene-10 tubing. In sham-operated animals,
the suture was placed beneath the left coronary artery without
ligation. Reperfusion of the endangered myocardium was character-
ized by typical hyperemia in the first few minutes. A piece of the
loosened suture was left in place to determine ischemic area during
termination. The chest wall was closed, and the animals subcutane-
ously received Antisedan (Pfizer) 2.5 mg/kg, Anexate (Roche) 0.5
mg/kg, and Temgesic (Schering-Plough) 0.1 mg/kg.
Generation of Chimeric Mice
We generated chimeric mice to study the relative contribution of
TLR2 expression in blood and parenchymal cells to myocardial I/R
injury. Donor bone marrow (BM) cells were collected from WT
C57Bl6 and TLR2
/ mice by flushing humerus, femurs, and tibiae
with RPMI-1640 medium. Recipient mice received 510
6 BM cells
after receiving a single dose of 7 Gy. Mice recovered for 6 weeks to
ensure stable engraftment of the donor BM cells. Hereafter, chimeriza-
tion was confirmed by phenotyping TLR2 expression on peripheral
blood samples with Cytomics FC500 (Beckman Coulter, Fullerton,
Calif) analysis. Successful chimerization (95% circulating donor
cells) was achieved in all mice (data not shown). Irradiated WT mice
with TLR2
/ BM are referred to as WT/TLR2
/ BM mice, and
TLR2
/ mice with WT BM are called TLR2
//WT BM mice.
Infarct Size
IS, determined 24 hours after myocardial I/R, is expressed as a
percentage of the area at risk (AAR). The ratio of AAR to left
ventricle (LV) is a measure of the extent of myocardial tissue that
underwent ischemia and reperfusion (ie, endangered area). The
IS/AAR ratio is an accurate measure to determine IS within
endangered myocardium and is the primary end point from which the
efficacy of treatment is assessed. To determine the AAR, the left
coronary artery was ligated once again (at the level marked by the
suture left in place), and 4% Evans Blue dye was injected via the
thoracic aorta in a retrograde fashion. Hearts were rapidly explanted,
rinsed in 0.9% saline, and put in a 20°C freezer for 1 hour. Then,
hearts were mechanically sliced into five 1-mm cross sections. Heart
sections were incubated in 1% triphenyltetrazolium chloride (Sigma-
Aldrich, St Louis, Mo) at 37°C for 15 minutes before being placed
in formaldehyde for another 15 minutes. Viable tissue stains red;
infarcted tissue appears white. Heart sections were digitally photo-
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AAR, and total LV area were measured with ImageJ software
(version 1.34).
Magnetic Resonance Imaging
Twenty-four mice (n8 per group) underwent serial assessment
of cardiac dimensions and function by high-resolution magnetic
resonance imaging (9.4 T; Bruker, Rheinstetten, Germany) under
isoflurane anesthesia before and 28 days after myocardial I/R
injury. Long-axis and short-axis images with a 1.0-mm interval
between slices were obtained and used to compute end-diastolic
volume (EDV; largest volume) and end-systolic volume (ESV;
smallest volume). Ejection fraction (EF) was calculated as
100(EDVESV)/EDV. All magnetic resonance imaging data were
analyzed with Qmass digital imaging software (Medis, Leiden, the
Netherlands).
NF-B Activation Assay
THP1-Blue-CD14 cells (Invitrogen, San Diego, Calif) were used for
in vitro efficacy assessment of OPN-301. Detailed information on
THP-1-Blue-CD14 cells is given in the online-only Data Supple-
ment. The THP1-Blue-CD14 cells were incubated for 30 minutes
with OPN-301 or IgG isotype, followed by 18 hours of incubation at
37°C with Pam-3-CSK4 (P3C; 100 ng/mL) or lipopolysaccharide (1
ng/mL). Quantification of NF-B activity was done according to the
manufacturer’s protocol.
Murine Tumor Necrosis Factor-
Production Assay
Mouse macrophage J774 cells (110
6/mL) were used for in vitro
efficacy assessment of OPN-301. Cells were coincubated with P3C
(100 ng/mL) in the presence of a dose range of OPN-301 and IgG1
isotype control. Six hours after incubation at 37°C/5% CO2, super-
natants were removed, and tumor necrosis factor- (TNF) was
assayed by ELISA (Duoset, RnD Systems, Abingdon, UK).
Immunohistochemistry
On termination, hearts were excised and snap-frozen in liquid
nitrogen. Frozen sections were stained for Ly-6G (for neutrophils: rat
anti-mouse Ly-6G 1:200, Abcam, Cambridge, UK), MAC-3 (for
macrophages: rat anti-mouse MAC-3 1:50, BD Pharmingen, Breda,
the Netherlands), and CD3 (for T lymphocytes: rabbit anti-human
CD3 1:100, Dako, Heverlee, Belgium) by overnight incubation with
the first antibody at 4°C for MAC-3 or by 1-hour incubation at room
temperature for Ly-6G and CD3. Detailed information on secondary
Figure 1. Circulating TLR2 expression mediates myocardial I/R
injury. IS as a percentage of AAR. Representative cross sections
after triphenyltetrazolium chloride staining are shown below the
corresponding bars. Each bar represents meanSEM; n10 per
group. *P0.019, †P0.014, ‡P0.013 vs saline.
Figure 2. OPN-301 prevents NF-B activation and TNF pro-
duction though selective inhibition of TLR2. A, NF-B activity
after P3C (100 ng/mL) stimulation in OPN-301– and IgG iso-
type– (ranging from 0 to 10 g/mL) treated THP-1 blue cells.
Note the dose response in OPN-301–treated cells. B, NF-B
activity in treated cells (OPN-301 and IgG isotype) after lipopoly-
saccharide (1 ng/mL) stimulation. Control NF-B activity in
ligand-treated cells without antibody (OPN-301 or IgG isotype)
was set as 1. All differences are signiﬁcant at P0.01. C, TNF
production in J774 cells. Note the dose response in OPN-301–
treated J774 cells. Each bar represents meanSEM from 3
independent experiments performed in duplicate. *P0.001,
unpaired Student t test.
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Supplement.
Quantification of scar area after 28 days of infarction was
performed with Picrosirius red staining of 4% formalin-fixed and
paraffin-embedded heart sections. Analysis was done with circularly
polarized light and digital image microscopy. Total scar area was
determined as the percentage positive staining of the LV wall.
Protein and RNA Isolation
Total RNA and protein were isolated from snap-frozen infarcted
heart sections with 1 mL Tripure Isolation Reagent (Roche, Basel,
Switzerland) according to the manufacturer’s protocol.
Caspase 3/7 Activity
The level of apoptosis after treatment was assessed with the
Caspase-Glo 3/7 assay kit (G8090, Promega, Madison, Wis). A
protein sample (1 mL) was diluted in 24 L assay buffer. The
remaining protocol followed manufacturer’s instructions.
Flow Cytometry
TLR2 and CD11b expression on circulating monocytes of EDTA
anticoagulated blood was analyzed by flow cytometry (Cytomics
FC500, Beckman Coulter). Whole blood was stained for TLR2
(FITC, eBioscience, San Diego, Calif), CD11b (FITC, Serotec,
Oxford, UK), and F4/80 for monocytes (Alexa Fluor 647, Serotec,
Oxford, UK). Peripheral blood composition was determined with
fluorescent antibodies for monocytes (CD14-FITC, BioLegend, San
Diego, Calif), neutrophils (Ly6G-APC, RnD Systems), and lympho-
cytes (CD3-FITC, eBioscience).
TNF, interleukin (IL)-1, IL-10, and granulocyte macrophage
colony-stimulating factor levels in isolated protein samples were
measured with the Th1/Th2 multiplex (Bender MedSystems, Vienna,
Austria). The protein samples were diluted 1:1 in assay buffer, and
the remaining protocol followed manufacturer’s instructions.
Phosphorylated target protein for p38-MAPK (Thr
180/Tyr
182) and
c-JNK (c-JNK; Thr
183/Tyr
185) was measured with the Bio-Plex
Multiplex Assay (Bio-Rad Laboratories, Hercules, Calif) according
to the manufacturer’s instructions after 1:8 dilution in assay buffer.
Polymerase Chain Reaction
Gene expression levels of monocyte chemotactic protein-1, intercel-
lular adhesion molecule-1, and vascular cell adhesion molecule-1
were quantified with quantitative polymerase chain reaction. Further
information is available in the online-only Data Supplement.
Statistical Analysis
Data are represented as meanSEM. One-way ANOVA with post
hoc 2-sided Dunnet t test adjustment (saline was set as control) was
used to compare IS between groups. Nonparametric t test for TLR2
expression data analysis and 1-way ANOVA post hoc least-
significant-difference test were used for comparison of cytokine and
protein levels between groups, and 1-way ANOVA post hoc Dunnett
T3 test was used for mRNA data. All statistical analyses were
performed with SPSS 15.1.1 (SPSS Inc, Chicago, Ill). Values of
P0.05 were considered significant.
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Figure 3. Anti-TLR2 treatment reduces IS. A, IS as a percentage of AAR on treatment with SB239063, IgG isotype, and OPN-301.
TLR2 KO serves as an illustrative control; n10 per group. *P0.001; †P0.016. B, Dose response of OPN-301 in IS reduction; n6
per group. *P0.028. TLR2 (C) and CD11b (D) expression levels in monocytes. No differences are observed at baseline and after 30
minutes of ischemia. After 1 hour of reperfusion, OPN-301 treatment inhibits both TLR2 (*P0.001) and CD11b (†P0.001 vs saline)
expression in monocytes; n5 per group. Each bar represents meanSEM. MFI indicates mean ﬂuorescence intensity.
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TLR2 on Hematopoietic Cells Mediates
Myocardial I/R Injury
With the use of an in vivo mouse model of myocardial I/R
injury (30 minutes of ischemia followed by reperfusion),
saline treatment resulted in 34.53.3% IS/AAR (Figure 1).
TLR2
/ mice showed an infarcted area of 232.9% (33%
reduction; P0.029). Final IS was determined by
hematopoiesis-derived TLR2. TLR2
//WT BM mice were
not protected against myocardial I/R injury, as shown by an
IS similar to that of saline-treated WT mice (33.93.2%
versus 34.53.3%; P1.0). WT/TLR2
/ BM mice were
protected against myocardial I/R injury to the same extent as
completely TLR2
/ mice, resulting in an 34% reduction in
IS (22.92.7% versus 34.53.3%; P0.024). The extent of
endangered myocardium was similar in all animals. The mean
AAR/LV ratio was 41% (Figure I of the online-only Data
Supplement). BM transplantation itself after radiation did not
affect final IS; no significant difference in IS occurred in
WT/WT BM and in TLR2
//TLR2
/ BM mice.
OPN-301 Selectively Inhibits Human Mononuclear
TLR2, Reduces IS, and Preserves Heart Function
In Vivo
Systemic inhibition of TLR2 could prevent myocardial I/R
injury because TLR2 on circulating cells mediates myocar-
dial I/R injury. Hence, we studied the therapeutic potential of
OPN-301, a novel monoclonal antibody against TLR2. OPN-
301 is a mouse IgG1 antibody that inhibits TLR2-mediated
responses in mouse, pig, monkey, and humans (data not
shown), indicating that it is specific for a critical epitope. The
IC50 for OPN-301 in human peripheral blood monocytes
Figure 4. Cardiac function and geometry at baseline and 28 days after infarction. A, Saline treatment results in a 22.812.3% increase
in ESV and a 13.96.9% increase in EDV. However, OPN-301 treatment preserves ESV and EDV. Sham operation does not affect car-
diac function and geometry; n8 per group. *P0.021, †P0.046 vs saline treatment. B, Scar area as a percentage of the LV in mice
after 28 days of infarction. *P0.003 vs saline treatment. C, Representative 4-chamber magnetic resonance images and scarred tissue
(Picrosirius red staining) 28 days after myocardial I/R injury. Each bar represents meanSEM.
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for both IL-1 and IL-6 (25 ng/mL).
NF-B activation is inhibited in human mononuclear
THP-1 cells pretreated with OPN-301 after P3C stimulation
(selective ligand for TLR2; Figure 2A). However, NF-B
activation does occur after lipopolysaccharide stimulation
pretreated with OPN-301 (Figure 2B). These results demon-
strate that OPN-301 selectively inhibits TLR2 signaling.
Furthermore, OPN-301 prevents NF-B activation in a dose-
dependent manner (Figure 2A). TNF production after P3C
stimulation in a mouse macrophage cell line was also highly
inhibited in cells pretreated with OPN-301 compared with
IgG1 isotype control (Figure 2C). In vivo, a single dose of
OPN-301 administered 5 minutes before reperfusion reduces
IS to 18.92.2% (45% reduction; P0.001 vs saline;
Figure 3A). In addition, the IS reduction reveals a dose-
dependent correlation (Figure 3B). Neither IgG isotype nor
SB239063 treatments reduce IS, resulting in 31.42.7%
(P0.931 versus saline) and 31.72.4% (P0.956 vs saline)
infarction within the AAR, respectively (Figure 3A).
AAR/LV was similar between treatment groups (P0.937
versus saline treatment; Figure I of the online-only Data
Supplement). Both TLR2 and CD11b expression in mono-
cytes decreased until the end of the 30-minute ischemic
period, whereas 1 hour of reperfusion caused an increase in
TLR2 and CD11b expression. Postreperfusion TLR2 and
CD11b expression in monocytes was inhibited on anti-TLR2
treatment (Figure 3C and 3D).
In concordance with the extensive infarct development,
saline treatment significantly deteriorated LV volumes and
EF (Figure 4A and Movie I in the online-only Data Supple-
ment). In contrast, OPN-301–treated animals showed pre-
served LV volumes and cardiac performance, as shown by
significantly smaller ESV (P0.021) and EDV (P0.046)
and higher EF (P0.009) compared with saline treatment
(Figure 4A and Movie II in the online-only Data Supple-
ment). Furthermore, OPN-301–treated animals showed pre-
served regional LV function. Systolic wall thickening in both
remote and infarct areas and EF were significantly higher in
OPN-301–treated animals (the Table). In line with the pre-
vention of reperfusion injury (Figure 3), mice treated with
anti-TLR2 antibody exhibited reduced scar formation after
28 days of infarction (Figure 4B and 4C). No difference
was observed in any of the hemodynamic parameters
measured (ie, heart rate, blood pressure) between animals
(data not shown).
Anti-TLR2 Treatment Reduces Inflammation
After Myocardial I/R Injury In Vivo
To further elucidate the role of leukocytes in our treated
animals, we studied the influx of neutrophils and macro-
phages after myocardial I/R injury. OPN-301 treatment re-
sulted in reduced neutrophil influx after 1 hour, 1 day, and 3
days of reperfusion compared with both saline and IgG
isotype treatment (Figure 5A). After 1 day, macrophages
entered the myocardium to remove necrotic cells (eg, neutro-
phils, myocytes) and debris, contributing to post-MI extra-
cellular matrix remodeling.6 OPN-301–treated animals
showed a reduction of macrophage influx, consistent with our
previous observation (Figure 5B). T-lymphocyte influx was
also highly reduced in OPN-301–treated animals after 1 hour
and 1 day of reperfusion (Figure 5C and 5D; remaining
representative sections are shown in Figures II through IV in
the online-only Data Supplement). The reduced influx of
leukocytes after OPN-301 treatment may have been caused
by changes in peripheral blood composition on treatment.
Whole-blood analyses revealed no differences between saline
and OPN-301 treatment after 1 and 3 days of reperfusion
(Figure V in the online-only Data Supplement).
In addition, we studied cytokine and chemokine expression
levels in ischemic/reperfused hearts. Mice treated with OPN-
301 showed diminished tissue TNF levels at all time points,
whereas saline and IgG isotype treatment resulted in in-
creased levels of TNF (Figure 6A). A significant reduction
of OPN-301 treatment was also seen in the levels of IL-1 (at
1 day reperfusion; Figure 6B), IL-10 (at all time points;
Figure 6C), and granulocyte macrophage colony-stimulating
factor levels (responsible for monocyte maturation and acti-
vation) at all time points (Figure 6D). We performed quan-
titative polymerase chain reaction to investigate whether the
highly reduced inflammation at tissue level depended on
changes in chemotactic and adhesive factors in the heart. At
the mRNA level, monocyte chemotactic protein-1, intercel-
lular adhesion molecule-1, and vascular cell adhesion
molecule-1 expression did not correlate with the observed
decrease in leukocyte infiltration. Although expression levels
were the same at 1 hour of reperfusion, monocyte chemotac-
tic protein-1 and intercellular adhesion molecule-1 were
significantly decreased on OPN-301 treatment after 1 day of
Table. Wall Thickness, Systolic Wall Thickening, and EF 28 Days After Reperfusion Injury
Saline OPN-301
Baseline
28 Days After Myocardial
I/R Injury Baseline
28 Days After Myocardial
I/R Injury
Wall thickness, septum (remote), mm 0.790.02 0.810.02 0.760.01 0.810.02
Wall thickness, free wall (infarct), mm 0.830.01 0.920.05 0.860.03 0.900.03
Systolic wall thickening, septum (remote), % 43.74.4 33.33.2 48.53.3 49.04.8†
Systolic wall thickening, free wall (infarct), % 54.81.4 3.36.0* 50.23.9 22.04.4*‡
EF, % 42.62.1 39.92.2 45.82.4 51.02.1§
Data are given as meanSEM; n8 per group.
Mann–Whitney U test: *P0.001 versus baseline; †P0.021, ‡P0.038, and §P0.009 versus saline treatment.
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with saline; see Table I of the online-only Data Supplement).
Anti-TLR2 Treatment Inhibits Proapoptotic
Signaling Pathways After Myocardial I/R Injury
In Vivo
Having established that anti-TLR2 treatment with OPN-301
is a potent suppressor of key markers of inflammation, we
next sought to examine the effects of OPN-301 on critical
signaling pathways involved in cardiac function and remod-
eling. Anti-TLR2–treated mice exhibited less activation of
proapoptotic signaling pathways than did mice treated with
saline treatment. At all time points after reperfusion, the
levels of phosphorylated c-JNK (Figure 7A) and phosphory-
lated p38-MAPK were significantly decreased (Figure 7B). In
line with this observation, OPN-301–treated animals showed
highly reduced caspase 3/7 activity levels after 1 hour and 1
day of reperfusion (Figure 7C).
Discussion
Many advances in clinical cardiology for the treatment of
acute MI have aimed at restoring epicardial flow in the
occluded coronary artery. Indeed, restored epicardial flow
is a prerequisite for cardiomyocyte salvage; however,
injury to both endothelial cells and cardiomyocytes occurs
as a result of reperfusion therapy. As a consequence of
restored flow, both myocardial perfusion and cardiomyo-
cyte survival are hampered, causing a paradoxical increase
in cell death and deterioration in cardiac function. Since
the phenomenon of myocardial I/R injury was first de-
scribed by Jennings et al19 in 1960, a significant amount of
research has been conducted to elucidate the mechanisms
that underlie myocardial I/R injury and to investigate
cardioprotective interventions. Despite the increased
knowledge about underlying mechanisms, none of the
experimental interventions has proved to be effective in
the clinic. Only a few have been shown to reduce surrogate
markers of myocardial I/R injury20 or to have an effect on
Figure 5. Anti-TLR2 treatment reduces leukocyte inﬂux after myocardial I/R injury. A, Number of neutrophils in the infarcted area in
treated animals after 1 hour, 1 day, and 3 days of reperfusion. *P0.006, **P0.001, ***P0.008 vs saline; †P0.018, ††P0.04,
†††P0.04 vs IgG isotype treatment. B, Number of macrophages after myocardial I/R injury. *P0.001 vs saline; †P0.004 vs IgG iso-
type treatment. C, Number of T lymphocytes after myocardial I/R injury. *P0.002, **P0.08 vs saline; †P0.046, ††P0.041 vs IgG
isotype treatment. D, Representative sections of neutrophil (1 day after myocardial I/R injury), macrophage (3 days after myocardial I/R
injury), and T-lymphocyte (1 day after myocardial I/R injury) inﬂux. Each bar represents meanSEM; n6 per group per time point.
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myocardial I/R injury is a complex pathological condi-
tion22 for which a clinical therapy remains a great chal-
lenge. The discovery of TLRs in the cardiovascular system
has greatly contributed to our knowledge of how the
inflammatory reaction initiates and enhances myocardial
I/R injury and postinfarct remodeling.23 Furthermore, pre-
vious studies using TLR-knockout animals provide evi-
dence for TLRs as novel therapeutic targets in the cardio-
vascular system.
We have shown that TLR2-dependent circulating blood
components mediate myocardial I/R injury. Interestingly, our
study is supported by earlier observations in which ex vivo
Langendorff-perfused hearts showed similar IS after myocar-
dial I/R injury.14,24 Feng et al24 and Sakata et al14 showed
similar IS after global myocardial I/R injury in MyD88
/
(downstream of both TLR2 and TLR4) and TLR2
/ hearts
compared with WT littermates. Our study shows that circu-
lating, not parenchymal, TLR2 determines final IS, which
explains the negative observations in Langendorff-perfused
heart experiments.
Our experiments demonstrate that anti-TLR2 treatment
could potentially be applied successfully in human patients
with acute MI. First, we used a novel anti-TLR2 monoclonal
antibody treatment to inhibit TLR signaling in vivo, which
can potentially be used in humans. Second, we chose a
clinically applicable time point for drug administration in the
setting of acute MI. Finally, 28-day survival experiments
demonstrate the long-term efficacy of an anti-TLR2 treat-
ment. We have demonstrated that treatment of mice with
OPN-301 reduces IS by 45% and prevents subsequent
deterioration of cardiac function and geometry after a single
intravenous bolus just 5 minutes before reperfusion. Hence, it
has the potential to be effective when administered to patients
Figure 6. Anti-TLR2 treatment reduces tissue levels of inﬂammatory cytokines. A, TNF levels are almost diminished on OPN-301 treat-
ment after myocardial I/R injury. *P0.016, **P0.039, ***P0.047 vs saline; †P0.036, ††P0.001, †††P0.031 vs IgG isotype treat-
ment. B, IL-1 levels. *P0.018 vs saline; †P0.007, ††P0.038 vs IgG isotype treatment. C, IL-10 levels are almost diminished on
OPN-301 treatment. *P0.034, **P0.002, ***P0.013 vs saline; †P0.05 vs IgG isotype treatment. D, Reduced granulocyte macro-
phage colony-stimulating factor (GM-CSF) levels on OPN-301 treatment. *P0.033, **P0.017, ***P0.041 vs saline; †P0.042 vs IgG
isotype treatment. Each bar represents meanSEM; n6 per group per time point.
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reperfusion therapy through primary percutaneous translumi-
nal coronary angioplasty. Our model also showed that the
p38-MAPK inhibitor SB239063 did not reduce IS when
given in the late ischemic period before reperfusion. We
chose this compound as a positive control because of exper-
imental data showing that it was effective when administered
before ischemia.25 Our study emphasizes the importance of a
clinically relevant model (ie, in which compounds are given
in the late ischemic period) to test therapeutic drugs in the
preclinical stage.
OPN-301 exerts its action by selectively inhibiting TLR2
signaling in leukocytes. It suppresses leukocyte infiltration in
the post–ischemic/reperfused myocardium partly via CD11b
downregulation without affecting peripheral blood composi-
tion. Levels of highly potent inflammatory cytokines in-
volved in cardiomyocyte injury and cardiac dysfunction
(reviewed in Reference 6) are substantially decreased or even
diminished. The decreased levels of cytokines are consistent
with the reduction in IS and preserved heart function. In
addition, decreased neutrophil, macrophage, and
T-lymphocyte infiltration occurs on OPN-301 treatment and
is not likely due to decreased chemotaxis and adhesion but
rather to decreased activation of these leukocyte subsets.
Only the expression of monocyte chemotactic protein-1 is
significantly decreased on day 1 after myocardial I/R injury.
Decreased infiltration, however, is already seen after 1 hour
of reperfusion, and an IS increase does not occur beyond the
first day. This is in accordance with our notion that circulat-
ing TLR2 plays a crucial role in myocardial I/R injury and not
parenchymal TLR2. The exact mechanism by which TLR2
inhibition leads to decreased leukocyte infiltration remains to
be addressed. One possible mechanism is that TLR2 inhibi-
tion prevents activation of circulating cells by endogenous
Figure 7. Proapoptotic signaling in hearts after myocardial I/R injury. A, Phosphorylated c-JNK levels are decreased on OPN-301 treat-
ment. *P0.049, **P0.024, ***P0.001 vs saline; †P0.005, ††P0.045 vs IgG isotype treatment. B, Phosphorylated p38-MAPK lev-
els. *P0.044, **P0.016, ***P0.008 vs saline; †P0.006 vs IgG isotype treatment. C, Caspase 3/7 levels. *P0.005, **P0.005 vs
saline; †P0.03, ††P0.024 vs IgG isotype treatment. Each bar represents meanSEM; n6 per group per time point. Phosphopro-
tein levels are expressed as picograms per milliliter; caspase 3/7 activity, as relative light units (RLU). Both assessments are corrected
for total protein concentration.
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myocyte necrosis (eg, HMGB1) may act as an activating
ligand for TLRs.26
Our study also demonstrates that IgG isotype antibody,
used as a negative control in our experiments, has several
nonsignificant antiinflammatory effects. It does not reduce
IS; however, compared with saline treatment, we do observe
a slightly decreased neutrophil influx (Figure 5A) and slightly
reduced IL-1 (at 3 days), IL-10 (at 1 and 3 days), and
granulocyte macrophage colony-stimulating factor (at 3 days;
Figure 6) levels. These observations point toward binding of
IgG isotype antibodies to membrane-bound Fc receptor. This
notion must be considered when isotype controls are used,
especially in in vitro assays using single cells (lacking total
organ functional assessments) with inflammatory markers as
a readout.
Conclusions
Our study shows that myocardial I/R injury is mediated by
TLR2-dependent blood components. Inhibition of TLR2 with
OPN-301 reduces myocardial I/R injury and preserves car-
diac function and geometry in vivo. The main mode of action
of OPN-301 is the prevention of detrimental NF-B–medi-
ated inflammation by reducing leukocyte infiltration, reduc-
ing cytokine production, and reducing proapoptotic signaling
and apoptosis. Moreover, our study demonstrates that OPN-
301 is a good candidate as an adjunctive therapeutic for
patients undergoing percutaneous transluminal coronary an-
gioplasty because it has been shown to be effective when
administered at a clinically applicable time point.
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CLINICAL PERSPECTIVE
Over the past few decades, many molecular targets have been studied to limit the excessive tissue loss that occurs during
the reperfusion phase after ischemia. This so-called myocardial ischemia/reperfusion injury limits the full potential of
reperfusion therapy. Unfortunately, successful clinical translation of preclinical promises remains to be established. Our
understanding of the pathogenesis of myocardial ischemia/reperfusion injury became much clearer with the discovery of
Toll-like receptors (TLRs). The role of innate immunity in cardiac ischemia appeared to be more pivotal than we thought.
More important, TLRs hold great promise as a therapeutic target within the innate immune system, also beyond cardiac
ischemia, without affecting host defense or proper scar formation after infarction. In the present study, we show the first
therapeutic application of an anti-TLR2 antibody after myocardial ischemia and reperfusion. We found that circulating
TLR2 mediates myocardial ischemia/reperfusion injury. Administration of a TLR2 antagonist just 5 minutes before
reperfusion reduces infarct size and improves cardiac performance and geometry. Furthermore, antagonizing TLR2 reduces
inflammation and cell death after infarction. Our results reappraised the critical role of TLRs in cardiac ischemia and
elucidated the mechanisms by which TLR2 mediates myocardial ischemia/reperfusion injury. Our results establish TLR2
as a novel therapeutic target for the treatment of acute myocardial infarction, even when it is initiated in the late ischemic
period. For this reason, we provide a rationale for anti-TLR2 treatment initiated either in the ambulance or in the
catheterization laboratory before reperfusion.
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